|MDACC Study No:||2011-0847 (clinicaltrials.gov NCT No: NCT01603212)|
|Title:||Systemic Therapy of Metastatic Melanoma with Multidrug Regimen Including Interferon, Interleukin-2 and BRAF Inhibitor|
|Principal Investigator:||Rodabe N. Amaria|
|Treatment Agent:||Interferon alfa 2b; Interleukine 2; PLX-4032|
|Study Description:||The goal of the Phase I part of this clinical research study is to find the |
highest tolerable dose of vemurafenib and Aldesleukin (interleukin-2) that can
be given in combination with interferon alfa-2b in patients with advanced or
metastatic melanoma. The safety of this combination will also be studied.
The goal of Phase II is to learn if this study drug combination can help to
control advanced or metastatic melanoma.